Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Other Non-Current Liabilities (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $1.1 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Other Non-Current Liabilities rose 56.84% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Sep 2023, up 56.84%, and an annual FY2022 reading of $1.1 million, up 36.09% over the prior year.
  • Other Non-Current Liabilities was $1.1 million for Q3 2023 at Terns Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.1 million in Q3 2023 and bottomed at $654000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 4 years is $837416.7, with a median of $768000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities grew 6.62% in 2022, then skyrocketed 56.84% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $657000.0 in 2020, then grew by 19.79% to $787000.0 in 2021, then skyrocketed by 36.09% to $1.1 million in 2022, then increased by 3.83% to $1.1 million in 2023.
  • Business Quant data shows Other Non-Current Liabilities for TERN at $1.1 million in Q3 2023, $1.1 million in Q2 2023, and $1.1 million in Q1 2023.